Overview of Bariatric Surgeries: Management and Complications
Main Article Content
Keywords
Obesity ; Bariatric Surgeries: Management ; Complications
Abstract
Around 1.9 billion individuals and children who were 18 years old and older were overweight. Approximately 650 million people were obese. 39% of adults over the age of 18 were overweight or obese in 2016, with 13% of them being obese. Overweight and obesity cause more fatalities than underweight in the majority of the world's population. Many factors could contribute to the rising obesity epidemic. The initial treatment goal is usually a modest weight loss 5% to 10% of your total weight. The burden of obesity is even more complex as the impact of obesity is a result of its comorbidities rather than a direct effect, which makes it more difficult to estimate the burden of obesity. The treatment methods that are right for you depend on your obesity severity, your overall health and your willingness to participate in your weight-loss plan. Bariatric surgeries are classified as having restrictive or malabsorptive properties. Restrictive surgeries reduce the volume of food that can be consumed at one time, leading to reduced total caloric intake. The aim of the present study was to review the bariatric surgeries management and its associated complications.
References
1- Nittari, G., Scuri, S., Sagaro, G. G., Petrelli, F., & Grappasonni, I. (2020). Epidemiology of obesity in children and adolescents. Teamwork in Healthcare, 20.
2- World Health Organization. (2020). The double burden of malnutrition: Priority actions on ending childhood obesity. World Health Organization. Regional Office for South-East Asia.
3- Gebremichael, M. A., Mengesha, M. M., Hailegebrea, S., Abdulkadir, H., & Wolde, B. B. (2021). Prevalence of Overweight/Obesity and Associated Factors Among Under-Five Children in Ethiopia: Evidence From the 2019 Ethiopia Mini Demographic and Health Survey (Emdhs); A Multilevel Analysis.
4- Deniz, S., Şirin, H., Kıvrak, M., Kaplan, Z., Ketrez, G., & Üner, S. (2020). Factors associated with overweight and obesity in students of 5-14 age group in Mersin. Gülhane Tip Dergisi, 62(4), 245.
5- Soliman, N., Huseth-Zosel, A., & Soliman, A. T. (2021). Obesity and overweight in children below 5 years of age: environmental, behavioural and social factors and their active use in prevention and management. World Nutrition, 12(4), 190-212.
6- Le, G. B. (2022). Prevalence and associated factors of overweight and obesity among primary school children: a cross-sectional study in Thanhhoa City, Vietnam. BMJ open, 12(4), e058504.
7- Tanveer, M., Hohmann, A., Roy, N., Zeba, A., Tanveer, U., & Siener, M. (2022). The current prevalence of underweight, overweight, and obesity associated with demographic factors among Pakistan school-aged children and adolescents—An empirical cross-sectional study. International Journal of Environmental Research and Public Health, 19(18), 11619.
8- Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016). Long-term side effects of glucocorticoids. Expert opinion on drug safety, 15(4), 457-465.
9- Gunay-Aygun, M., Cassidy, S. B., & Nicholls, R. D. (1997). Prader–Willi and other syndromes associated with obesity and mental retardation. Behavior genetics, 27, 307-324.
10- Crinò, A., Fintini, D., Bocchini, S., & Grugni, G. (2018). Obesity management in Prader–Willi syndrome: Current perspectives. Diabetes, metabolic syndrome and obesity: targets and therapy, 579-593.
11- Diamanti-Kandarakis, E., Papalou, O., Kandaraki, E. A., & Kassi, G. (2017). Mechanisms in endocrinology: nutrition as a mediator of oxidative stress in metabolic and reproductive disorders in women. European journal of endocrinology, 176(2), R79-R99.
12- Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary syndrome. Clinical endocrinology, 95(4), 531-541.
13- Gordon-Elliott, J. (2016). Fundamentals of diagnosing and treating eating disorders: A clinical casebook. Springer.
14- Thaler, J. P., Guyenet, S. J., Dorfman, M. D., Wisse, B. E., & Schwartz, M. W. (2013). Hypothalamic inflammation: marker or mechanism of obesity pathogenesis?. Diabetes, 62(8), 2629-2634.
15- Rippe, J. M., & Hess, S. (1998). The role of physical activity in the prevention and management of obesity. Journal of the American Dietetic Association, 98(10), S31-S38.
16- Hills, A. P., & Byrne, N. M. (2004). Physical activity in the management of obesity. Clinics in Dermatology, 22(4), 315-318.
17- Leermakers, E. A., Dunn, A. L., & Blair, S. N. (2000). Exercise management of obesity. Medical Clinics, 84(2), 419-440.
18- Hession, M., Rolland, C., Kulkarni, U., Wise, A., & Broom, J. (2009). Systematic review of randomized controlled trials of low‐carbohydrate vs. low‐fat/low‐calorie diets in the management of obesity and its comorbidities. Obesity reviews, 10(1), 36-50.
19- Botchlett, R., & Wu, C. (2018). Diet composition for the management of obesity and obesity-related disorders. Journal of diabetes mellitus and metabolic syndrome, 3, 10.
20- Patel, D. (2015). Pharmacotherapy for the management of obesity. Metabolism, 64(11), 1376-1385.
21- Henness, S., & Perry, C. M. (2006). Orlistat: a review of its use in the management of obesity. Drugs, 66, 1625-1656.
22- Smith, S. M., Meyer, M., & Trinkley, K. E. (2013). Phentermine/topiramate for the treatment of obesity. Annals of Pharmacotherapy, 47(3), 340-349.
23- Sweeting, A. N., Tabet, E., Caterson, I. D., & Markovic, T. P. (2014). Management of obesity and cardiometabolic risk–role of phentermine/extended release topiramate. Diabetes, metabolic syndrome and obesity: targets and therapy, 35-44.
24- Apovian, C. M. (2016). Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future cardiology, 12(2), 129-138.
25- Scott, L. J. (2015). Liraglutide: a review of its use in the management of obesity. Drugs, 75, 899-910.
26- Lin, C. H., Shao, L., Zhang, Y. M., Tu, Y. J., Zhang, Y., Tomlinson, B., Liu, Z. (2020). An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert opinion on pharmacotherapy, 21(3), 275-285.
27- Hess, R., & Cross, L. B. (2013). The safety and efficacy of lorcaserin in the management of obesity. Postgraduate medicine, 125(6), 62-72.
28- Shah, R., Davitkov, P., Dayyeh, B. K. A., Saumoy, M., & Murad, M. H. (2021). AGA technical review on intragastric balloons in the management of obesity. Gastroenterology, 160(5), 1811-1830.
29- Farina, M. G., Baratta, R., Nigro, A., Vinciguerra, F., Puglisi, C., Schembri, R., ... & Frittitta, L. (2012). Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obesity surgery, 22, 565-571.
30- Shah, R., Davitkov, P., Dayyeh, B. K. A., Saumoy, M., & Murad, M. H. (2021). AGA technical review on intragastric balloons in the management of obesity. Gastroenterology, 160(5), 1811-1830.
31- Hachem, A., & Brennan, L. (2016). Quality of life outcomes of bariatric surgery: a systematic review. Obesity surgery, 26, 395-409.
32- Piche, M. E., Auclair, A., Harvey, J., Marceau, S., & Poirier, P. (2015). How to choose and use bariatric surgery in 2015. Canadian Journal of Cardiology, 31(2), 153-166.
33- Diamantis, T., Apostolou, K. G., Alexandrou, A., Griniatsos, J., Felekouras, E., & Tsigris, C. (2014). Review of long-term weight loss results after laparoscopic sleeve gastrectomy. Surgery for Obesity and Related Diseases, 10(1), 177-183.
34- Pequignot, A., Prevot, F., Dhahri, A., Rebibo, L., Badaoui, R., & Regimbeau, J. M. (2015). Is sleeve gastrectomy still contraindicated for patients aged≥ 60 years? A case-matched study with 24 months of follow-up. Surgery for Obesity and Related Diseases, 11(5), 1008-1013.
35- Lazzati, A., De Antonio, M., Paolino, L., Martini, F., Azoulay, D., Iannelli, A., & Katsahian, S. (2017). Natural history of adjustable gastric banding: lifespan and revisional rate. Annals of surgery, 265(3), 439-445.
36- Lee, W. J., Ser, K. H., Lee, Y. C., Tsou, J. J., Chen, S. C., Chen, J. C. (2012). Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obesity surgery, 22, 1827-1834.
37- Biertho, L., Simon-Hould, F., Marceau, S., Lebel, S., Lescelleur, O., & Biron, S. (2016). Current outcomes of laparoscopic duodenal switch. Annals of surgical innovation and research, 10, 1-5.
38- Marceau, P., Biron, S., Marceau, S., Hould, F. S., Lebel, S., Lescelleur, O., Kral, J. G. (2014). Biliopancreatic diversion-duodenal switch: independent contributions of sleeve resection and duodenal exclusion. Obesity surgery, 24, 1843-1849.
39- Lim, R., Beekley, A., Johnson, D. C., & Davis, K. A. (2018). Early and late complications of bariatric operation. Trauma surgery & acute care open, 3(1).
40- Montravers, P., Augustin, P., Zappella, N., Dufour, G., Arapis, K., Chosidow, D., Desmard, M. (2015). Diagnosis and management of the postoperative surgical and medical complications of bariatric surgery. Anaesthesia Critical Care & Pain Medicine, 34(1), 45-52.
41- Walsh, C., & Karmali, S. (2015). Endoscopic management of bariatric complications: a review and update. World Journal of Gastrointestinal Endoscopy, 7(5), 518.
42- Vedantam, S., & Roberts, J. (2020). Endoscopic stents in the management of bariatric complications: our algorithm and outcomes. Obesity Surgery, 30, 1150-1158.
43- Hamdan, K., Somers, S., & Chand, M. (2011). Management of late postoperative complications of bariatric surgery. Journal of British Surgery, 98(10), 1345-1355.
44- Abell, T. L., & Minocha, A. (2006). Gastrointestinal complications of bariatric surgery: diagnosis and therapy. The American journal of the medical sciences, 331(4), 214-218.
45- Richter, J. E. (2013). Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clinical Gastroenterology and Hepatology, 11(5), 465-471.
46- Ashrafi, D., Osland, E., & Memon, M. A. (2020). Bariatric surgery and gastroesophageal reflux disease. Annals of Translational Medicine, 8(Suppl 1).
47- Becker, D. A., Balcer, L. J., & Galetta, S. L. (2012). The neurological complications of nutritional deficiency following bariatric surgery. Journal of obesity, 2012.
48- Portincasa, P., Di Ciaula, A., de Bari, O., Garruti, G., Palmieri, V. O., & Wang, D. H. (2016). Management of gallstones and its related complications. Expert review of gastroenterology & hepatology, 10(1), 93-112.
49- Morais, M., Faria, G., Preto, J., & Costa-Maia, J. (2016). Gallstones and bariatric surgery: to treat or not to treat?. World journal of surgery, 40, 2904-2910.
50- Chang, J., Corcelles, R., Boules, M., Jamal, M. H., Schauer, P. R., & Kroh, M. D. (2016). Predictive factors of biliary complications after bariatric surgery. Surgery for Obesity and Related Diseases, 12(9), 1706-1710.
2- World Health Organization. (2020). The double burden of malnutrition: Priority actions on ending childhood obesity. World Health Organization. Regional Office for South-East Asia.
3- Gebremichael, M. A., Mengesha, M. M., Hailegebrea, S., Abdulkadir, H., & Wolde, B. B. (2021). Prevalence of Overweight/Obesity and Associated Factors Among Under-Five Children in Ethiopia: Evidence From the 2019 Ethiopia Mini Demographic and Health Survey (Emdhs); A Multilevel Analysis.
4- Deniz, S., Şirin, H., Kıvrak, M., Kaplan, Z., Ketrez, G., & Üner, S. (2020). Factors associated with overweight and obesity in students of 5-14 age group in Mersin. Gülhane Tip Dergisi, 62(4), 245.
5- Soliman, N., Huseth-Zosel, A., & Soliman, A. T. (2021). Obesity and overweight in children below 5 years of age: environmental, behavioural and social factors and their active use in prevention and management. World Nutrition, 12(4), 190-212.
6- Le, G. B. (2022). Prevalence and associated factors of overweight and obesity among primary school children: a cross-sectional study in Thanhhoa City, Vietnam. BMJ open, 12(4), e058504.
7- Tanveer, M., Hohmann, A., Roy, N., Zeba, A., Tanveer, U., & Siener, M. (2022). The current prevalence of underweight, overweight, and obesity associated with demographic factors among Pakistan school-aged children and adolescents—An empirical cross-sectional study. International Journal of Environmental Research and Public Health, 19(18), 11619.
8- Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016). Long-term side effects of glucocorticoids. Expert opinion on drug safety, 15(4), 457-465.
9- Gunay-Aygun, M., Cassidy, S. B., & Nicholls, R. D. (1997). Prader–Willi and other syndromes associated with obesity and mental retardation. Behavior genetics, 27, 307-324.
10- Crinò, A., Fintini, D., Bocchini, S., & Grugni, G. (2018). Obesity management in Prader–Willi syndrome: Current perspectives. Diabetes, metabolic syndrome and obesity: targets and therapy, 579-593.
11- Diamanti-Kandarakis, E., Papalou, O., Kandaraki, E. A., & Kassi, G. (2017). Mechanisms in endocrinology: nutrition as a mediator of oxidative stress in metabolic and reproductive disorders in women. European journal of endocrinology, 176(2), R79-R99.
12- Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary syndrome. Clinical endocrinology, 95(4), 531-541.
13- Gordon-Elliott, J. (2016). Fundamentals of diagnosing and treating eating disorders: A clinical casebook. Springer.
14- Thaler, J. P., Guyenet, S. J., Dorfman, M. D., Wisse, B. E., & Schwartz, M. W. (2013). Hypothalamic inflammation: marker or mechanism of obesity pathogenesis?. Diabetes, 62(8), 2629-2634.
15- Rippe, J. M., & Hess, S. (1998). The role of physical activity in the prevention and management of obesity. Journal of the American Dietetic Association, 98(10), S31-S38.
16- Hills, A. P., & Byrne, N. M. (2004). Physical activity in the management of obesity. Clinics in Dermatology, 22(4), 315-318.
17- Leermakers, E. A., Dunn, A. L., & Blair, S. N. (2000). Exercise management of obesity. Medical Clinics, 84(2), 419-440.
18- Hession, M., Rolland, C., Kulkarni, U., Wise, A., & Broom, J. (2009). Systematic review of randomized controlled trials of low‐carbohydrate vs. low‐fat/low‐calorie diets in the management of obesity and its comorbidities. Obesity reviews, 10(1), 36-50.
19- Botchlett, R., & Wu, C. (2018). Diet composition for the management of obesity and obesity-related disorders. Journal of diabetes mellitus and metabolic syndrome, 3, 10.
20- Patel, D. (2015). Pharmacotherapy for the management of obesity. Metabolism, 64(11), 1376-1385.
21- Henness, S., & Perry, C. M. (2006). Orlistat: a review of its use in the management of obesity. Drugs, 66, 1625-1656.
22- Smith, S. M., Meyer, M., & Trinkley, K. E. (2013). Phentermine/topiramate for the treatment of obesity. Annals of Pharmacotherapy, 47(3), 340-349.
23- Sweeting, A. N., Tabet, E., Caterson, I. D., & Markovic, T. P. (2014). Management of obesity and cardiometabolic risk–role of phentermine/extended release topiramate. Diabetes, metabolic syndrome and obesity: targets and therapy, 35-44.
24- Apovian, C. M. (2016). Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future cardiology, 12(2), 129-138.
25- Scott, L. J. (2015). Liraglutide: a review of its use in the management of obesity. Drugs, 75, 899-910.
26- Lin, C. H., Shao, L., Zhang, Y. M., Tu, Y. J., Zhang, Y., Tomlinson, B., Liu, Z. (2020). An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert opinion on pharmacotherapy, 21(3), 275-285.
27- Hess, R., & Cross, L. B. (2013). The safety and efficacy of lorcaserin in the management of obesity. Postgraduate medicine, 125(6), 62-72.
28- Shah, R., Davitkov, P., Dayyeh, B. K. A., Saumoy, M., & Murad, M. H. (2021). AGA technical review on intragastric balloons in the management of obesity. Gastroenterology, 160(5), 1811-1830.
29- Farina, M. G., Baratta, R., Nigro, A., Vinciguerra, F., Puglisi, C., Schembri, R., ... & Frittitta, L. (2012). Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obesity surgery, 22, 565-571.
30- Shah, R., Davitkov, P., Dayyeh, B. K. A., Saumoy, M., & Murad, M. H. (2021). AGA technical review on intragastric balloons in the management of obesity. Gastroenterology, 160(5), 1811-1830.
31- Hachem, A., & Brennan, L. (2016). Quality of life outcomes of bariatric surgery: a systematic review. Obesity surgery, 26, 395-409.
32- Piche, M. E., Auclair, A., Harvey, J., Marceau, S., & Poirier, P. (2015). How to choose and use bariatric surgery in 2015. Canadian Journal of Cardiology, 31(2), 153-166.
33- Diamantis, T., Apostolou, K. G., Alexandrou, A., Griniatsos, J., Felekouras, E., & Tsigris, C. (2014). Review of long-term weight loss results after laparoscopic sleeve gastrectomy. Surgery for Obesity and Related Diseases, 10(1), 177-183.
34- Pequignot, A., Prevot, F., Dhahri, A., Rebibo, L., Badaoui, R., & Regimbeau, J. M. (2015). Is sleeve gastrectomy still contraindicated for patients aged≥ 60 years? A case-matched study with 24 months of follow-up. Surgery for Obesity and Related Diseases, 11(5), 1008-1013.
35- Lazzati, A., De Antonio, M., Paolino, L., Martini, F., Azoulay, D., Iannelli, A., & Katsahian, S. (2017). Natural history of adjustable gastric banding: lifespan and revisional rate. Annals of surgery, 265(3), 439-445.
36- Lee, W. J., Ser, K. H., Lee, Y. C., Tsou, J. J., Chen, S. C., Chen, J. C. (2012). Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obesity surgery, 22, 1827-1834.
37- Biertho, L., Simon-Hould, F., Marceau, S., Lebel, S., Lescelleur, O., & Biron, S. (2016). Current outcomes of laparoscopic duodenal switch. Annals of surgical innovation and research, 10, 1-5.
38- Marceau, P., Biron, S., Marceau, S., Hould, F. S., Lebel, S., Lescelleur, O., Kral, J. G. (2014). Biliopancreatic diversion-duodenal switch: independent contributions of sleeve resection and duodenal exclusion. Obesity surgery, 24, 1843-1849.
39- Lim, R., Beekley, A., Johnson, D. C., & Davis, K. A. (2018). Early and late complications of bariatric operation. Trauma surgery & acute care open, 3(1).
40- Montravers, P., Augustin, P., Zappella, N., Dufour, G., Arapis, K., Chosidow, D., Desmard, M. (2015). Diagnosis and management of the postoperative surgical and medical complications of bariatric surgery. Anaesthesia Critical Care & Pain Medicine, 34(1), 45-52.
41- Walsh, C., & Karmali, S. (2015). Endoscopic management of bariatric complications: a review and update. World Journal of Gastrointestinal Endoscopy, 7(5), 518.
42- Vedantam, S., & Roberts, J. (2020). Endoscopic stents in the management of bariatric complications: our algorithm and outcomes. Obesity Surgery, 30, 1150-1158.
43- Hamdan, K., Somers, S., & Chand, M. (2011). Management of late postoperative complications of bariatric surgery. Journal of British Surgery, 98(10), 1345-1355.
44- Abell, T. L., & Minocha, A. (2006). Gastrointestinal complications of bariatric surgery: diagnosis and therapy. The American journal of the medical sciences, 331(4), 214-218.
45- Richter, J. E. (2013). Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clinical Gastroenterology and Hepatology, 11(5), 465-471.
46- Ashrafi, D., Osland, E., & Memon, M. A. (2020). Bariatric surgery and gastroesophageal reflux disease. Annals of Translational Medicine, 8(Suppl 1).
47- Becker, D. A., Balcer, L. J., & Galetta, S. L. (2012). The neurological complications of nutritional deficiency following bariatric surgery. Journal of obesity, 2012.
48- Portincasa, P., Di Ciaula, A., de Bari, O., Garruti, G., Palmieri, V. O., & Wang, D. H. (2016). Management of gallstones and its related complications. Expert review of gastroenterology & hepatology, 10(1), 93-112.
49- Morais, M., Faria, G., Preto, J., & Costa-Maia, J. (2016). Gallstones and bariatric surgery: to treat or not to treat?. World journal of surgery, 40, 2904-2910.
50- Chang, J., Corcelles, R., Boules, M., Jamal, M. H., Schauer, P. R., & Kroh, M. D. (2016). Predictive factors of biliary complications after bariatric surgery. Surgery for Obesity and Related Diseases, 12(9), 1706-1710.
Article Sidebar
Published
Dec 13, 2022
Article Details
How to Cite
Ahmed M. Sallam; Abdelrahman Sarhan; Tamer Wasefy; Omar Mahmoud Agwa; Walid A. Mawla. (2022). Overview of Bariatric Surgeries: Management and Complications. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 434–446. https://doi.org/10.53555/jptcp.v29i04.3857
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.